NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. The company is headquartered in Emeryville, California and currently employs 14 full-time employees. The company went IPO on 2007-10-26. The firm manufactures and sells its proprietary form of hypochlorous acid for the wound care market through its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries.
根據最新的財務報表(Form-10K),Hingham Institution For Savings 的總資產為 $0,淨isProfitable}為 $0
NBY 的關鍵財務比率是什麼?
Hingham Institution For Savings 的流動比率為 0,淨利潤率為 0,每股銷售為 $0。
NovaBay Pharmaceuticals Inc 的收入按細分市場或地理位置如何劃分?
Hingham Institution For Savings 最大收入來源為 Banking and Related Activities,在最近的收益報告中收入為 65,852,999。就地區而言,United States 是 Hingham Institution For Savings 的主要市場,收入為 65,852,999。
NovaBay Pharmaceuticals Inc 是否盈利?
無,根據最新的財務報表,Hingham Institution For Savings 的淨損失為 $0